

CAROL WERTHER JOINS H.C. WAINWRIGHT AS SENIOR BIOTECHNOLOGY ANALYST

NEW YORK, December 3, 2015 – H.C. Wainwright & Co., LLC (“HCW”) announced today that Carol Ann Werther has joined the firm as a Managing Director and Senior Biotechnology Analyst in the Firm’s Equity Research Group.

Ms. Werther joins HCW with over 20 years of experience in the biotechnology sector both as a research analyst and portfolio manager. She has previously been a senior analyst at CRT Capital Group, Summer Street Research Partners, Think Equity Partners, Adams, Harkness & Hill and Cowen & Co. She also was a biotechnology portfolio manager at INVESCO Trust Company and Rothschild Asset Management, Ltd.

“We are excited to have Carol join HCW’s biotech research team as our 7th senior analyst” commented Mark Viklund, Chief Executive Officer of HCW. “Her depth of knowledge in the biotechnology sector acquired over her distinguished career will enable HCW to provide differentiated investment advice to our clients”.

About H.C. Wainwright & Co., LLC

H.C. Wainwright & Co., LLC is an investment bank dedicated to providing corporate finance, strategic advisory and related services to public and private growth companies across multiple sectors and regions. The H.C. Wainwright team has been the leader in the PIPE (private investment in public equity) and RD (registered direct offering) transaction markets. H.C. Wainwright was established in 1868 and is headquartered in New York City.